CCL20 and cancer: Similarly, WO2017011559A1 (anti-CCL20 Abs) can bind to CCL20 and inhibit the interaction between CCR6 and CCL20, thereby mediating the inhibition of Treg/Th17 recruitment to the tumors, which can inhibit cancer stem cell activity and the tumorigenesis (141).